Because PD-L1 and PD-1 are dynamic biomarkers as well as the immune system, assessing their expression in primary tumor tissue may not provide an overview of metastatic disease, which evolves during tumor progression [21]. This evidence concerns the gene PDCD1 and neoplasm.